Dr. Mark Hurle has 25 years of experience in drug discovery and development. Most recently, he serves as Director of Computational Biology at GlaxoSmithKline, where he has been part of their Systematic Drug Repositioning group, which develops novel drug/disease hypotheses using molecular and literature evidence. Dr Hurle has experience in problem-solving computational biology including integrated analysis, gene expression, gene analysis, protein homology and structure. His specialties include Omic data analysis, protein folding and structure, and exploratory analysis of clinical/preclinical data.

Dr. Hurle got his Bachelor in Science from the Massachusetts Institute of Technology and his PhD from Penn State University.